Differential Bone Marrow Homing Capacity of VLA-4 and CD38 High Expressing Chronic Lymphocytic Leukemia Cells

Modifying Akt signaling in B-cell chronic lymphocytic leukemia cells.

Lysine Residue at Position 22 of the AID Protein Regulates Its Class Switch Activity

Differential Bone Marrow Homing Capacity of VLA-4 and CD38 High Expressing Chronic Lymphocytic Leukemia Cells

Development of CLL in the TCL1 transgenic mouse model is associated with severe skewing of the T-cell compartment homologous to human CLL.

Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemia.

Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia.

MicroRNAs as biomarkers for the diagnosis and prognosis of human cancer.

microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia.

Interdependent regulation of p53 and miR-34a in chronic lymphocytic leukemia.

Riding the 2-edged sword.

An uncommon cause of anaemia: Sheehan's syndrome.

Apoptosis of leukocytes triggered by acute DNA damage promotes lymphoma formation.

PKCbeta is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKCbeta as a therapeutic target in chronic lymphocytic leukemia.

The molecular and cellular biology of chronic lymphocytic leukemia as the basis for novel therapeutic approaches.

Novel therapeutics approaches to chronic lymphocytic leukemia based on recent biological insights.

Bim and Bmf in tissue homeostasis and malignant disease.

The effect of IgVH mutational status on the induction of apoptosis by rituximab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: evidence from a clinical phase I/II trial.

Expression levels of CD38 in T cells predict course of disease in male patients with B-chronic lymphocytic leukemia.

Analysis of Bcl-2 protein expression in chronic lymphocytic leukemia: a comparison of three semiquantitation techniques

Expression of functional Interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma.

Differential sensitivity of CD4+ and CD8+ T lymphocytes to the killing efficacy of Fas(Apo-1/CD95) ligand+ tumor cells in B chronic lymphocytic leukemia.

IL-10 serum levels in B-cell chronic lymphocytic leukaemia.

Modulation of Apo-1/Fas (CD95)-induced programmed cell death in myeloma cells by interferon-alpha 2.

Lysine Residue at Position 22 of the AID Protein Regulates Its Class Switch Activity

Differential Bone Marrow Homing Capacity of VLA-4 and CD38 High Expressing Chronic Lymphocytic Leukemia Cells

Development of CLL in the TCL1 transgenic mouse model is associated with severe skewing of the T-cell compartment homologous to human CLL.

Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemia.

Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia.

MicroRNAs as biomarkers for the diagnosis and prognosis of human cancer.

microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia.

Interdependent regulation of p53 and miR-34a in chronic lymphocytic leukemia.

Riding the 2-edged sword.

An uncommon cause of anaemia: Sheehan's syndrome.

Apoptosis of leukocytes triggered by acute DNA damage promotes lymphoma formation.

PKCbeta is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKCbeta as a therapeutic target in chronic lymphocytic leukemia.

The molecular and cellular biology of chronic lymphocytic leukemia as the basis for novel therapeutic approaches.

Novel therapeutics approaches to chronic lymphocytic leukemia based on recent biological insights.

Bim and Bmf in tissue homeostasis and malignant disease.

The effect of IgVH mutational status on the induction of apoptosis by rituximab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: evidence from a clinical phase I/II trial.

Expression levels of CD38 in T cells predict course of disease in male patients with B-chronic lymphocytic leukemia.

Analysis of Bcl-2 protein expression in chronic lymphocytic leukemia: a comparison of three semiquantitation techniques

Expression of functional Interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma.

Differential sensitivity of CD4+ and CD8+ T lymphocytes to the killing efficacy of Fas(Apo-1/CD95) ligand+ tumor cells in B chronic lymphocytic leukemia.

IL-10 serum levels in B-cell chronic lymphocytic leukaemia.

Modulation of Apo-1/Fas (CD95)-induced programmed cell death in myeloma cells by interferon-alpha 2.

An uncommon cause of anaemia: Sheehan's syndrome.

Lysine Residue at Position 22 of the AID Protein Regulates Its Class Switch Activity

Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia.

Lysine Residue at Position 22 of the AID Protein Regulates Its Class Switch Activity

Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia.

Canonical and Noncanonical Hedgehog/GLI Signaling in Hematological Malignancies.

Lysine Residue at Position 22 of the AID Protein Regulates Its Class Switch Activity

Chemokine-dependent B cell-T cell interactions in chronic lymphocytic leukemia and multiple myeloma - targets for therapeutic intervention?

Antimyeloma activity of the sesquiterpene lactone cnicin: impact on Pim-2 kinase as a novel therapeutic target.

Differential Bone Marrow Homing Capacity of VLA-4 and CD38 High Expressing Chronic Lymphocytic Leukemia Cells

Novel Therapeutic Options in Anaplastic Large Cell Lymphoma: Molecular Targets and Immunological Tools.

ASH Report. Novel agents in diffuse large B-cell lymphoma: A short update including ASH 2010.

Development of CLL in the TCL1 transgenic mouse model is associated with severe skewing of the T-cell compartment homologous to human CLL.

Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemia.

Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia.

MicroRNAs as biomarkers for the diagnosis and prognosis of human cancer.

Inhibition of GLI, but not Smoothened, induces apoptosis in chronic lymphocytic leukemia cells.

microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia.

Interdependent regulation of p53 and miR-34a in chronic lymphocytic leukemia.

An uncommon cause of anaemia: Sheehan's syndrome.

Modifying Akt signaling in B-cell chronic lymphocytic leukemia cells.

Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma.

Neue Therapie in Sicht.

PKCbeta is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKCbeta as a therapeutic target in chronic lymphocytic leukemia.

Circulating B-cell chronic lymphocytic leukemia cells display impaired migration to lymphnodes and bone marrow.

The molecular and cellular biology of chronic lymphocytic leukemia as the basis for novel therapeutic approaches.

Difference in the relative distribution of CD4+ T-cell subsets in B-CLL with mutated and unmutated immunoglobulin (Ig) VH genes: implication for the course of disease.

Novel therapeutics approaches to chronic lymphocytic leukemia based on recent biological insights.

SNP309 as predictor for sensitivity of CLL cells to the MDM2 inhibitor nutlin-3a.

MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia.

Arsenic Trioxide induces apoptosis preferably in B-CLL cells of high risk patients including del17p13.

Tumour-immune cell interactions modulated by chemokines.

The effect of IgVH mutational status on the induction of apoptosis by rituximab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: evidence from a clinical phase I/II trial.

Expression levels of CD38 in T cells predict course of disease in male patients with B-chronic lymphocytic leukemia.

IL-4 inhibits the TNF-alpha induced proliferation of renal cell carcinoma (RCC) and cooperates with TNF-alpha to induce apoptotic and cytokine responses by RCC: implications for antitumor immune responses.

A role of TRAIL in killing osteoblasts by myeloma cells.

Polyacetylenes from the Apiaceae Vegetables Carrot, Celery, Fennel, Parsley, and Parsnip and Their Cytotoxic Activities.

1,10-Epoxyhypocretenolides from the Azorean Endemic Leontodon rigens (Asteraceae)

Up-regulation of functional chemokine receptor CCR3 in human renal cell carcinoma.

Transendothelial migration of myeloma cells is increased by tumor necrosis factor (TNF)-alpha via TNF receptor 2 and autocrine up-regulation of MCP-1.

Elevated levels of soluble CD44 are associated with advanced disease and in vitro proliferation of neoplastic lymphocytes in B-cell chronic lymphocytic leukaemia.

Tetrocarcin-A-induced ER stress mediates apoptosis in B-CLL cells via a Bcl-2--independent pathway.

Tracking death dealing by Fas and TRAIL in lymphatic neoplastic disorders: pathways, targets, and therapeutic tools.

Tuning the rheostat of the myelopoietic system via Fas and TRAIL.

Stressful death of T-ALL tumor cells after treatment with the anti-tumor agent Tetrocarcin-A.

Histone deacetylase inhibitors potently repress CXCR4 chemokine receptor expression and function in acute lymphoblastic leukaemia.

Interleukin-15 as a potential costimulatory cytokine in CD154 gene therapy of chronic lymphocytic leukemia.

Resveratrol, a tumor-suppressive compound from grapes, induces apoptosis via a novel mitochondrial pathway controlled by bcl-2.

Inhibition of histone deacetylase activity enhances Fas receptor-mediated apoptosis in leukemic lymphoblasts.

Analysis of Bcl-2 protein expression in chronic lymphocytic leukemia: a comparison of three semiquantitation techniques

Expression of functional Interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma.

Gastric cancer cell lines lack Fas Ligand (FasL) expression but kill T cells via a FasL-independent pathway.

Resveratrol causes arrest in the S-phase prior to Fas-independent apoptosis in CEM-C7H2 acute leukemia cells.

Differential sensitivity of CD4+ and CD8+ T lymphocytes to the killing efficacy of Fas(Apo-1/CD95) ligand+ tumor cells in B chronic lymphocytic leukemia.

IL-10 serum levels in B-cell chronic lymphocytic leukaemia.

Modulation of Apo-1/Fas (CD95)-induced programmed cell death in myeloma cells by interferon-alpha 2.

Canonical and Noncanonical Hedgehog/GLI Signaling in Hematological Malignancies.

Lysine Residue at Position 22 of the AID Protein Regulates Its Class Switch Activity

Chemokine-dependent B cell-T cell interactions in chronic lymphocytic leukemia and multiple myeloma - targets for therapeutic intervention?

Antimyeloma activity of the sesquiterpene lactone cnicin: impact on Pim-2 kinase as a novel therapeutic target.

Differential Bone Marrow Homing Capacity of VLA-4 and CD38 High Expressing Chronic Lymphocytic Leukemia Cells

Novel Therapeutic Options in Anaplastic Large Cell Lymphoma: Molecular Targets and Immunological Tools.

ASH Report. Novel agents in diffuse large B-cell lymphoma: A short update including ASH 2010.

Development of CLL in the TCL1 transgenic mouse model is associated with severe skewing of the T-cell compartment homologous to human CLL.

Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemia.

Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia.

MicroRNAs as biomarkers for the diagnosis and prognosis of human cancer.

Inhibition of GLI, but not Smoothened, induces apoptosis in chronic lymphocytic leukemia cells.

microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia.

Interdependent regulation of p53 and miR-34a in chronic lymphocytic leukemia.

An uncommon cause of anaemia: Sheehan's syndrome.

Modifying Akt signaling in B-cell chronic lymphocytic leukemia cells.

Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma.

Neue Therapie in Sicht.

PKCbeta is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKCbeta as a therapeutic target in chronic lymphocytic leukemia.

Circulating B-cell chronic lymphocytic leukemia cells display impaired migration to lymphnodes and bone marrow.

The molecular and cellular biology of chronic lymphocytic leukemia as the basis for novel therapeutic approaches.

Difference in the relative distribution of CD4+ T-cell subsets in B-CLL with mutated and unmutated immunoglobulin (Ig) VH genes: implication for the course of disease.

Novel therapeutics approaches to chronic lymphocytic leukemia based on recent biological insights.

SNP309 as predictor for sensitivity of CLL cells to the MDM2 inhibitor nutlin-3a.

MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia.

Arsenic Trioxide induces apoptosis preferably in B-CLL cells of high risk patients including del17p13.

Tumour-immune cell interactions modulated by chemokines.

The effect of IgVH mutational status on the induction of apoptosis by rituximab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: evidence from a clinical phase I/II trial.

Expression levels of CD38 in T cells predict course of disease in male patients with B-chronic lymphocytic leukemia.

IL-4 inhibits the TNF-alpha induced proliferation of renal cell carcinoma (RCC) and cooperates with TNF-alpha to induce apoptotic and cytokine responses by RCC: implications for antitumor immune responses.

A role of TRAIL in killing osteoblasts by myeloma cells.

Polyacetylenes from the Apiaceae Vegetables Carrot, Celery, Fennel, Parsley, and Parsnip and Their Cytotoxic Activities.

1,10-Epoxyhypocretenolides from the Azorean Endemic Leontodon rigens (Asteraceae)

Up-regulation of functional chemokine receptor CCR3 in human renal cell carcinoma.

Transendothelial migration of myeloma cells is increased by tumor necrosis factor (TNF)-alpha via TNF receptor 2 and autocrine up-regulation of MCP-1.

Elevated levels of soluble CD44 are associated with advanced disease and in vitro proliferation of neoplastic lymphocytes in B-cell chronic lymphocytic leukaemia.

Tetrocarcin-A-induced ER stress mediates apoptosis in B-CLL cells via a Bcl-2--independent pathway.

Tracking death dealing by Fas and TRAIL in lymphatic neoplastic disorders: pathways, targets, and therapeutic tools.

Tuning the rheostat of the myelopoietic system via Fas and TRAIL.

Stressful death of T-ALL tumor cells after treatment with the anti-tumor agent Tetrocarcin-A.

Histone deacetylase inhibitors potently repress CXCR4 chemokine receptor expression and function in acute lymphoblastic leukaemia.

Interleukin-15 as a potential costimulatory cytokine in CD154 gene therapy of chronic lymphocytic leukemia.

Resveratrol, a tumor-suppressive compound from grapes, induces apoptosis via a novel mitochondrial pathway controlled by bcl-2.

Inhibition of histone deacetylase activity enhances Fas receptor-mediated apoptosis in leukemic lymphoblasts.

Analysis of Bcl-2 protein expression in chronic lymphocytic leukemia: a comparison of three semiquantitation techniques

Expression of functional Interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma.

Gastric cancer cell lines lack Fas Ligand (FasL) expression but kill T cells via a FasL-independent pathway.

Resveratrol causes arrest in the S-phase prior to Fas-independent apoptosis in CEM-C7H2 acute leukemia cells.

Differential sensitivity of CD4+ and CD8+ T lymphocytes to the killing efficacy of Fas(Apo-1/CD95) ligand+ tumor cells in B chronic lymphocytic leukemia.

IL-10 serum levels in B-cell chronic lymphocytic leukaemia.

Modulation of Apo-1/Fas (CD95)-induced programmed cell death in myeloma cells by interferon-alpha 2.

Canonical and Noncanonical Hedgehog/GLI Signaling in Hematological Malignancies.

Chemokine-dependent B cell-T cell interactions in chronic lymphocytic leukemia and multiple myeloma - targets for therapeutic intervention?

Differential Bone Marrow Homing Capacity of VLA-4 and CD38 High Expressing Chronic Lymphocytic Leukemia Cells

Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia.

Inhibition of GLI, but not Smoothened, induces apoptosis in chronic lymphocytic leukemia cells.

Erforschung der Chronisch Lymphatischen Leukämie am LIMCR.

ÖGHO-Frühjahrstagung: Chronische Lymphatische Leukämie, Adhäsionsmoleküle als mögliche therapeutische Ziele.

Modifying Akt signaling in B-cell chronic lymphocytic leukemia cells.

CCL19 is a specific ligand of the constitutively recycling atypical human chemokine receptor CRAM-B.

Circulating B-cell chronic lymphocytic leukemia cells display impaired migration to lymphnodes and bone marrow.

The molecular and cellular biology of chronic lymphocytic leukemia as the basis for novel therapeutic approaches.

Novel therapeutics approaches to chronic lymphocytic leukemia based on recent biological insights.

A crosstalk between intracellular CXCR7 and CXCR4 involved in rapid CXCL12-triggered integrin activation but not integrin activation but not in chemokine-triggered motility of human T lymphocytes and CD34+ cells.

Canonical and Noncanonical Hedgehog/GLI Signaling in Hematological Malignancies.

Chemokine-dependent B cell-T cell interactions in chronic lymphocytic leukemia and multiple myeloma - targets for therapeutic intervention?

Differential Bone Marrow Homing Capacity of VLA-4 and CD38 High Expressing Chronic Lymphocytic Leukemia Cells

Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia.

Inhibition of GLI, but not Smoothened, induces apoptosis in chronic lymphocytic leukemia cells.

Erforschung der Chronisch Lymphatischen Leukämie am LIMCR.

ÖGHO-Frühjahrstagung: Chronische Lymphatische Leukämie, Adhäsionsmoleküle als mögliche therapeutische Ziele.

Modifying Akt signaling in B-cell chronic lymphocytic leukemia cells.

CCL19 is a specific ligand of the constitutively recycling atypical human chemokine receptor CRAM-B.

Circulating B-cell chronic lymphocytic leukemia cells display impaired migration to lymphnodes and bone marrow.

The molecular and cellular biology of chronic lymphocytic leukemia as the basis for novel therapeutic approaches.

Novel therapeutics approaches to chronic lymphocytic leukemia based on recent biological insights.

A crosstalk between intracellular CXCR7 and CXCR4 involved in rapid CXCL12-triggered integrin activation but not integrin activation but not in chemokine-triggered motility of human T lymphocytes and CD34+ cells.

ASH Report. Novel agents in diffuse large B-cell lymphoma: A short update including ASH 2010.

ASH Report. Novel agents in diffuse large B-cell lymphoma: A short update including ASH 2010.

Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemia.

An uncommon cause of anaemia: Sheehan's syndrome.

ASH Report. Novel agents in diffuse large B-cell lymphoma: A short update including ASH 2010.

Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemia.

An uncommon cause of anaemia: Sheehan's syndrome.

Antimyeloma activity of the sesquiterpene lactone cnicin: impact on Pim-2 kinase as a novel therapeutic target.

Anaplastic large cell lymphoma: the current state of play from a European prospective as presented at the second annual meeting of the European Research Initiative on ALCL, 27-28 June 2011.

Novel Therapeutic Options in Anaplastic Large Cell Lymphoma: Molecular Targets and Immunological Tools.

microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia.

Interdependent regulation of p53 and miR-34a in chronic lymphocytic leukemia.

Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma.

Neue Therapie in Sicht.

Arsenic Trioxide induces apoptosis preferably in B-CLL cells of high risk patients including del17p13.

Mitochondrial phosphate-carrier deficiency: a novel disorder of oxidative phosphorylation.

Antimyeloma activity of the sesquiterpene lactone cnicin: impact on Pim-2 kinase as a novel therapeutic target.

Anaplastic large cell lymphoma: the current state of play from a European prospective as presented at the second annual meeting of the European Research Initiative on ALCL, 27-28 June 2011.

Novel Therapeutic Options in Anaplastic Large Cell Lymphoma: Molecular Targets and Immunological Tools.

microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia.

Interdependent regulation of p53 and miR-34a in chronic lymphocytic leukemia.

Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma.

Neue Therapie in Sicht.

Arsenic Trioxide induces apoptosis preferably in B-CLL cells of high risk patients including del17p13.

Mitochondrial phosphate-carrier deficiency: a novel disorder of oxidative phosphorylation.

An uncommon cause of anaemia: Sheehan's syndrome.

The molecular and cellular biology of chronic lymphocytic leukemia as the basis for novel therapeutic approaches.

Novel therapeutics approaches to chronic lymphocytic leukemia based on recent biological insights.

Tumour-immune cell interactions modulated by chemokines.

microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia.

Arsenic Trioxide induces apoptosis preferably in B-CLL cells of high risk patients including del17p13.

microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia.

Arsenic Trioxide induces apoptosis preferably in B-CLL cells of high risk patients including del17p13.

Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemia.

Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia.

An uncommon cause of anaemia: Sheehan's syndrome.

Difference in the relative distribution of CD4+ T-cell subsets in B-CLL with mutated and unmutated immunoglobulin (Ig) VH genes: implication for the course of disease.

Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemia.

Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia.

An uncommon cause of anaemia: Sheehan's syndrome.

Difference in the relative distribution of CD4+ T-cell subsets in B-CLL with mutated and unmutated immunoglobulin (Ig) VH genes: implication for the course of disease.